Vol. 1 No. 3 (2026), Articles
Vol. 1 No. 3 (2026)

The Role of Insulin Resistance and Thyroid Dysfunction in the Pathophysiology of Menstrual Cycle Disorders

Articles
Published 2026-03-14
Mukima Karimova
Head of the Department of Endocrinology, Hematology, and Phthisiology, PhD, Associate Professor. Fergana Medical Institute of Public Health
Noila Khabibullaeva
1st-year Master’s Student, Department of Endocrinology, Hematology, and Phthisiology. Fergana Medical Institute of Public Health
PDF

How to Cite

Karimova , M., & Khabibullaeva , N. (2026). The Role of Insulin Resistance and Thyroid Dysfunction in the Pathophysiology of Menstrual Cycle Disorders. INTERNATIONAL CONFERENCE ON MODERN RESEARCH AND SCIENTIFIC INNOVATION, 1(3), 25-30. https://doi.org/10.5281/zenodo.19019743
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

This study investigates the synergistic impact of insulin resistance (IR) and thyroid dysfunction on the development of menstrual irregularities in reproductive-aged women. Menstrual cycle disorders represent a significant clinical challenge, often serving as early indicators of underlying metabolic and endocrine imbalances. The research focused on evaluating the correlation between Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) values and serum levels of Thyroid Stimulating Hormone (TSH) in 120 patients presenting with oligomenorrhea and amenorrhea. Methods involved a comprehensive clinical assessment, biochemical screening, and hormonal profiling. Results indicated a statistically significant prevalence of subclinical hypothyroidism among patients with elevated HOMA-IR scores ($3.8 \pm 0.4$ vs $1.9 \pm 0.2$ in the control group, $p < 0.05$). The findings suggest that IR exacerbates thyroid-mediated disruptions of the hypothalamic-pituitary-ovarian axis, leading to chronic anovulation. Conclusion: Integrated screening for both metabolic and thyroid parameters is essential for the effective management of menstrual health, as mono-therapy often fails to restore cyclic stability when dual pathways of dysfunction coexist.

PDF

References

1. Azziz, R., et al. (2019). "The Polycystic Ovary Syndrome." Nature Reviews Disease Primers. DOI: 10.1038/nrdp.2016.57

2. Ganie, M. A., et al. (2020). "Thyroid dysfunction in women with PCOS." European Journal of Endocrinology. DOI: 10.1530/EJE-19-1002

3. Unuane, D., & Velkeniers, B. (2021). "Impact of thyroid disease on fertility and pregnancy outcomes." Endocrinology & Metabolism Clinics. DOI: 10.1016/j.ecl.2020.10.003

4. Kim, J. J., & Laven, J. S. (2022). "Metabolic phenotypes of PCOS." Fertility and Sterility. DOI: 10.1016/j.fertnstert.2021.12.025

5. World Health Organization (2023). "Women's reproductive health: Global statistics and trends."

6. Taylor, P. N., et al. (2018). "Global epidemiology of hyperthyroidism and hypothyroidism." Nature Reviews Endocrinology. DOI: 10.1038/nrendo.2018.18

7. Moran, L. J., et al. (2021). "Insulin resistance in reproductive age women." Molecular and Cellular Endocrinology. DOI: 10.1016/j.mce.2021.111258

8. Duntas, L. H. (2020). "Thyroid-ovarian axis: cycles of influence." Journal of Endocrinological Investigation. DOI: 10.1007/s40618-020-01257-2

9. Legro, R. S. (2022). "Evaluation and treatment of polycystic ovary syndrome." Endotext.

10. Wang, J., et al. (2021). "The prevalence of insulin resistance in subclinical hypothyroidism." Frontiers in Endocrinology. DOI: 10.3389/fendo.2021.643358